How to Calculate Weight Loss Percentage: The Formula That Actually Predicts Long-Term Success

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Weight loss percentage is calculated as [(starting weight minus current weight) divided by starting weight] times 100, not current weight in the denominator
• A 200-pound person losing 20 pounds achieves 10% loss; a 150-pound person losing the same 20 pounds achieves 13.3%, which predicts better metabolic outcomes
• The 5% threshold marks clinically significant weight loss; 10% marks substantial benefit; 15%+ on GLP-1 medications correlates with Type 2 diabetes remission rates above 60%
• Tracking percentage instead of absolute pounds eliminates the psychological distortion where heavier individuals appear more successful despite equivalent metabolic effort

Direct answer (40-60 words)

To calculate weight loss percentage: subtract your current weight from your starting weight, divide that number by your starting weight, then multiply by 100. The formula is [(starting weight - current weight) ÷ starting weight] × 100. A person starting at 200 pounds and reaching 180 pounds has lost 10%, not 11.1%.

Table of contents

1. The formula: why the denominator matters more than you think
2. The most common calculation error (and why it distorts your progress)
3. Why percentage matters more than pounds: the clinical evidence
4. The threshold percentages that predict long-term success
5. How to track percentage loss on GLP-1 medications
6. What most articles get wrong about "healthy" loss rates
7. The comparison problem: why your loss percentage isn't comparable to someone else's
8. When percentage tracking misleads (and when to use absolute metrics instead)
9. The decision tree: which metric to track when
10. Clinical pattern: what we see in compounded GLP-1 titration data
11. FAQ
12. Footer disclaimers

The formula: why the denominator matters more than you think

The correct formula for weight loss percentage:

[(Starting Weight - Current Weight) ÷ Starting Weight] × 100

Example: You start at 220 pounds. You currently weigh 198 pounds.

• Weight lost: 220 - 198 = 22 pounds
• Percentage: (22 ÷ 220) × 100 = 10%

The denominator is always your starting weight, never your current weight. This is not arbitrary. Using starting weight in the denominator makes the percentage a measure of how much of your original body mass you've lost, which is the clinically relevant question for metabolic health outcomes.

If you mistakenly use current weight as the denominator (22 ÷ 198 × 100), you get 11.1%, which overstates your progress and makes week-to-week comparisons meaningless because the denominator keeps changing.

The mathematical reason the denominator matters: weight loss percentage is meant to be a ratio of change to baseline. Changing the baseline mid-calculation destroys comparability. A patient who loses 10% of starting weight, regains 5%, then loses another 5% has not lost 10% twice. They've lost 10% once. The starting weight anchors the measurement.

The most common calculation error (and why it distorts your progress)

The error we see most often: dividing by current weight instead of starting weight, or recalculating "starting weight" every month.

Here's why this breaks tracking:

Week	Weight	Pounds Lost (Total)	Correct %	Incorrect % (using current weight)
0	200 lbs	0	0%	0%
4	190 lbs	10	5.0%	5.3%
8	182 lbs	18	9.0%	9.9%
12	176 lbs	24	12.0%	13.6%
16	172 lbs	28	14.0%	16.3%

By week 16, the incorrect method overstates progress by 2.3 percentage points. That might not sound like much, but it crosses the threshold from "clinically significant" (10% to 15%) into "substantial benefit" (15%+), which affects clinical decision-making about whether to continue escalating dose or maintain.

The second error: resetting "starting weight" after a plateau or regain. If you lose 20 pounds, regain 8, then start tracking again from the regain weight, you've artificially erased the regain from your percentage calculation. Your body didn't erase it. The metabolic adaptations that caused the regain are still present.

The correct approach: pick a true baseline (the weight you were when you started medication or when you decided to lose weight) and never change it. Track all subsequent weights as a percentage of that single baseline.

Why percentage matters more than pounds: the clinical evidence

Absolute weight loss in pounds is nearly useless for predicting health outcomes across different starting weights. Percentage loss is what correlates with metabolic improvement.

The evidence:

Diabetes remission. The DiRECT trial (Lean et al., The Lancet, 2018) tracked 298 patients with Type 2 diabetes through a weight-loss intervention. Remission rates by percentage lost:

Weight Loss %	Remission Rate at 12 Months
0-5%	7%
5-10%	34%
10-15%	57%
15%+	86%

A 250-pound person losing 25 pounds (10%) had nearly identical remission rates to a 180-pound person losing 18 pounds (10%). A 250-pound person losing 15 pounds (6%) had worse outcomes than a 150-pound person losing 15 pounds (10%), despite losing the same absolute weight.

Cardiovascular risk reduction. The Look AHEAD trial (Wing et al., Diabetes Care, 2011) found that each 1% of weight lost correlated with a 3% to 5% reduction in triglycerides and a 0.5 to 1 mmHg reduction in systolic blood pressure, independent of starting weight. The relationship was linear with percentage, not with pounds.

Liver fat reduction. Vilar-Gomez et al. (Gastroenterology, 2015) measured liver fat in NAFLD patients. A 10% weight loss reduced liver fat by an average of 40% regardless of starting BMI. Absolute weight loss showed no consistent correlation.

The mechanism: metabolic improvements are driven by reduction in adipose tissue mass relative to lean mass, not by the absolute number of pounds of fat lost. A 300-pound person losing 30 pounds of fat loses roughly the same proportion of adipose tissue as a 200-pound person losing 20 pounds, and both see similar insulin sensitivity improvements.

The threshold percentages that predict long-term success

The clinical literature consistently identifies three thresholds:

5% loss: Clinically significant.

• Measurable improvements in fasting glucose, HbA1c, blood pressure, and triglycerides
• The FDA's threshold for approving weight-loss medications
• Most patients on GLP-1 medications reach this within 8 to 12 weeks at maintenance dose

10% loss: Substantial benefit.

• Diabetes remission rates begin to climb steeply
• Sleep apnea severity improves by one category (severe to moderate, moderate to mild)
• Knee osteoarthritis pain scores improve by 20% to 30%
• The threshold where most patients report that weight loss "feels real" psychologically

15% loss: meaningful outcomes.

• Type 2 diabetes remission rates exceed 60% if sustained for 12+ months
• Cardiovascular event risk reduced by 15% to 20% in patients with established disease (SELECT trial, Lincoff et al., New England Journal of Medicine, 2023)
• The median outcome in SURMOUNT-1 for tirzepatide 15 mg at 72 weeks was 15.7% (Jastreboff et al., NEJM, 2022)

20%+ loss: Approaching surgical outcomes.

• Metabolic improvements comparable to bariatric surgery in many patients
• Achieved by roughly 30% to 40% of patients on tirzepatide 15 mg and 15% to 20% on semaglutide 2.4 mg
• The range where excess skin becomes a common concern

These thresholds apply regardless of starting weight. A 180-pound person reaching 153 pounds (15% loss) sees similar metabolic benefit to a 280-pound person reaching 238 pounds (15% loss).

How to track percentage loss on GLP-1 medications

The practical method for patients on semaglutide or tirzepatide:

Step 1: Establish a true baseline. Weigh yourself on the same scale, at the same time of day (morning, after using the bathroom, before eating), wearing similar clothing. This is Week 0. Record it.

Step 2: Weigh weekly, same conditions. Same scale, same time, same clothing state. Weight fluctuates 2 to 5 pounds day-to-day due to water, food volume, and bowel content. Weekly averages smooth this out.

Step 3: Calculate percentage weekly. Use the formula above. Track it in a spreadsheet or app. Most GLP-1 patients see:

• Weeks 0 to 4: 2% to 4% loss (mostly water and glycogen)
• Weeks 4 to 12: 1% to 1.5% loss per month (fat loss accelerates)
• Weeks 12 to 24: 1% to 2% loss per month (peak velocity on medication)
• Weeks 24+: 0.5% to 1% loss per month (approaching plateau)

Step 4: Compare to threshold benchmarks. At each clinical check-in (usually every 4 to 12 weeks), compare your percentage to the thresholds above. If you've reached 10% and your primary goal was diabetes management, you're in the substantial benefit range. If your goal is 15% and you're at 8% after 16 weeks, you're on track.

Step 5: Adjust expectations for regain. If you regain weight, continue calculating percentage from the original baseline. If you started at 200 pounds, lost to 170 (15% loss), then regained to 180, your current loss percentage is 10%, not 0%. This keeps the math honest.

What most articles get wrong about "healthy" loss rates

The common advice: "Healthy weight loss is 1 to 2 pounds per week."

This is wrong in two ways.

First, it ignores starting weight. One pound per week is 0.5% per week for a 200-pound person but 0.33% per week for a 300-pound person. The 300-pound person losing 1 pound per week is losing more slowly in relative terms, despite hitting the same absolute target.

The correct framing: healthy weight loss is 0.5% to 1% of body weight per week during active loss phases. For a 200-pound person, that's 1 to 2 pounds per week. For a 300-pound person, it's 1.5 to 3 pounds per week.

Second, it assumes linear loss. Real weight loss on GLP-1 medications is not linear. The STEP 1 trial (Wilding et al., NEJM, 2021) showed average semaglutide patients lost:

• Weeks 0 to 20: 0.35% per week (rapid phase)
• Weeks 20 to 52: 0.12% per week (plateau phase)
• Weeks 52 to 68: 0.04% per week (maintenance phase)

A patient losing 0.5% per week for 20 weeks, then 0.1% per week for the next 32 weeks is following the expected curve, not "failing." Articles that warn about "slowing progress" after month 4 misunderstand the pharmacology. GLP-1 medications don't stop working. You approach a new equilibrium weight where energy intake matches expenditure at the medication dose.

The clinical pattern we see: patients who lose faster than 1.5% per week in the first 12 weeks often report unsustainable nausea and higher discontinuation rates. Patients who lose slower than 0.3% per week after 16 weeks on a stable dose are often undertitrated or have uncorrected dietary patterns that counteract the medication.

The comparison problem: why your loss percentage isn't comparable to someone else's

Two patients both lose 12% of their starting weight on tirzepatide. Are their outcomes equivalent?

Not necessarily. The comparison breaks down across several variables:

Starting BMI. A patient starting at BMI 32 who loses 12% (reaching BMI 28.2) has moved from Class I obesity to overweight. A patient starting at BMI 42 who loses 12% (reaching BMI 37) remains in Class II obesity. Both achieved 12%, but the metabolic benefit differs because absolute BMI still matters for outcomes like joint stress and sleep apnea.

Body composition. A patient with high lean mass (muscular build) losing 12% loses more absolute fat than a patient with low lean mass losing 12%, because a larger fraction of their starting weight was muscle. The muscular patient sees better metabolic outcomes per percentage point lost.

Loss velocity. A patient who loses 12% over 16 weeks vs a patient who loses 12% over 40 weeks may have different outcomes. Rapid loss is associated with more lean mass loss (Cava et al., Journal of Obesity, 2017), which can reduce resting metabolic rate and make regain more likely.

Medication dose. A patient who loses 12% on semaglutide 1.0 mg has a different risk-benefit profile than a patient who needs tirzepatide 15 mg to achieve the same 12%. The higher-dose patient may have more severe underlying insulin resistance or leptin resistance.

The implication: percentage loss is the best single metric for tracking your own progress over time, but comparing your percentage to someone else's percentage is only loosely informative. The relevant comparison is your percentage to the clinical thresholds (5%, 10%, 15%), not to another individual's percentage.

When percentage tracking misleads (and when to use absolute metrics instead)

Percentage tracking fails in three scenarios:

1. Very high starting weights (BMI 50+). A patient starting at 400 pounds who loses 60 pounds (15%) has achieved a major metabolic milestone but still weighs 340 pounds and may face ongoing mobility limitations, joint damage, and sleep apnea. For this patient, absolute weight targets (getting below 300 pounds, below 250 pounds) may be more motivating and clinically relevant than percentage milestones.

2. Lean mass preservation goals. Percentage loss doesn't distinguish fat loss from muscle loss. A patient who loses 10% of starting weight but loses 6% fat and 4% muscle has a worse outcome than a patient who loses 10% of starting weight as 9% fat and 1% muscle. For patients focused on body composition (athletes, older adults at risk for sarcopenia), tracking fat mass via DEXA or bioimpedance is more useful than percentage.

3. Short-term fluctuations. A patient who starts at 200 pounds, drops to 197 pounds after a stomach virus (1.5% loss), then returns to 200 pounds didn't "regain 1.5%." They had a transient fluid and food-volume change. Percentage tracking is meaningful over 4+ week windows, not week-to-week.

The decision tree:

• If your goal is metabolic health improvement (diabetes, blood pressure, cholesterol): Track percentage. Compare to 5%, 10%, 15% thresholds.
• If your goal is functional improvement (mobility, joint pain, sleep apnea): Track percentage AND absolute weight. Some benefits (knee pain) correlate more with absolute load reduction.
• If your goal is body composition (muscle preservation, athletic performance): Track fat mass and lean mass separately via DEXA or bioimpedance, not total weight percentage.
• If your starting BMI is above 50: Track percentage to measure progress, but set absolute weight milestones (below 350, below 300) for motivation.

The decision tree: which metric to track when

Start here: What is your primary goal?

Goal: Reverse or improve Type 2 diabetes

• Primary metric: Weight loss percentage
• Target: 10% to 15% sustained loss
• Secondary metric: HbA1c, fasting glucose
• Check-in frequency: Every 4 weeks

Goal: Reduce cardiovascular risk

• Primary metric: Weight loss percentage
• Target: 10%+ sustained loss (SELECT trial threshold)
• Secondary metrics: Blood pressure, LDL cholesterol, triglycerides
• Check-in frequency: Every 8 to 12 weeks

Goal: Improve mobility or joint pain

• Primary metric: Absolute weight (pounds or kg)
• Target: Reduce load on joints by 20 to 40 pounds
• Secondary metric: Pain scores, distance walked without pain
• Check-in frequency: Every 4 weeks

Goal: Qualify for surgery or procedure (e.g., joint replacement, fertility treatment)

• Primary metric: Absolute weight or BMI
• Target: Specific BMI threshold (often BMI <35 or <40)
• Secondary metric: Percentage loss to track velocity
• Check-in frequency: Weekly

Goal: Improve body composition (preserve muscle while losing fat)

• Primary metric: Fat mass (via DEXA or bioimpedance)
• Target: Reduce fat mass by 15% to 25% while maintaining or gaining lean mass
• Secondary metric: Strength benchmarks (e.g., squat, deadlift)
• Check-in frequency: Every 8 to 12 weeks (DEXA frequency)

Goal: Aesthetic or personal (fit into specific clothing size, reach a goal weight)

• Primary metric: Absolute weight or clothing size
• Target: Patient-defined
• Secondary metric: Percentage to contextualize progress
• Check-in frequency: Weekly to monthly

Most patients benefit from tracking percentage as the primary metric and one secondary metric aligned with their specific goal.

Clinical pattern: what we see in compounded GLP-1 titration data

Across the patient population using compounded semaglutide and tirzepatide through FormBlends, we see consistent patterns in percentage loss by titration phase:

Titration phase (Weeks 0 to 12): Most patients lose 6% to 10% of starting weight. Loss is front-loaded: 3% to 5% in the first month (largely water and glycogen), then 1% to 1.5% per month in months 2 and 3. Patients who lose less than 4% by week 12 often benefit from dose escalation if tolerating current dose well.

Maintenance phase (Weeks 12 to 32): Loss continues at 0.8% to 1.2% per month. Cumulative loss by week 32 typically reaches 12% to 18% for patients on tirzepatide and 10% to 15% for patients on semaglutide. Patients who plateau before reaching 10% total loss often respond to a dose increase or dietary review.

Sustained phase (Week 32+): Loss velocity slows to 0.2% to 0.5% per month. Most patients reach a stable weight between months 8 and 14. The stable weight is typically 12% to 20% below starting weight, depending on medication, dose, and adherence.

Regain pattern: Patients who discontinue medication regain an average of 4% to 7% of starting weight within 12 months (Wilding et al., Diabetes, Obesity and Metabolism, 2022). Patients who continue medication at maintenance dose regain less than 2% on average. This suggests the medication is suppressing a biological drive to return to the original set point, not just creating a temporary caloric deficit.

The pattern that predicts long-term success: steady loss of 0.8% to 1.5% per month during months 2 through 8, followed by stabilization. Patients who lose faster (2%+ per month) often struggle with adherence due to side effects. Patients who lose slower (less than 0.5% per month after month 3) often need dose optimization or dietary intervention.

FAQ

How do I calculate my weight loss percentage? Subtract your current weight from your starting weight, divide by your starting weight, then multiply by 100. Formula: [(starting weight - current weight) ÷ starting weight] × 100. Example: starting at 180 pounds, now 162 pounds: (18 ÷ 180) × 100 = 10%.

Do I use my current weight or starting weight in the formula? Always use starting weight as the denominator. Current weight is the numerator (starting minus current). Using current weight in the denominator overstates your progress and makes tracking inconsistent.

What is a good weight loss percentage per month? During active weight loss on GLP-1 medications, 1% to 1.5% per month is typical and sustainable. The first month often shows 2% to 3% due to water loss. After 6 to 8 months, velocity slows to 0.5% per month or less as you approach a plateau.

Is 10% weight loss a lot? Yes. A 10% loss is the threshold for "substantial benefit" in clinical trials. It correlates with major improvements in diabetes markers, blood pressure, cholesterol, and joint pain. Most patients on GLP-1 medications reach 10% within 5 to 7 months.

How much weight loss percentage is noticeable? Most people begin to notice physical changes around 5% to 7% loss. Others typically notice around 8% to 10% loss. This varies by starting weight and where you carry fat. Facial changes often appear first.

What percentage of weight loss is considered significant? 5% is the clinical threshold for "significant" (measurable health improvements). 10% is "substantial" (major metabolic benefits). 15%+ is "meaningful" (outcomes approaching bariatric surgery in some patients).

Should I reset my starting weight after a plateau? No. Keep your original starting weight as the baseline for all calculations. If you lose 20 pounds, plateau for 3 months, then lose another 10 pounds, your total loss is 30 pounds from the original baseline, not 10 pounds from the plateau weight.

How do you calculate weight loss percentage on a calculator? Enter your starting weight. Subtract your current weight. Divide the result by your starting weight. Multiply by 100. Example on calculator: 200 (start) - 180 (current) = 20. Then 20 ÷ 200 = 0.10. Then 0.10 × 100 = 10%.

Why is percentage better than pounds for tracking weight loss? Percentage accounts for different starting weights. A 200-pound person losing 20 pounds (10%) achieves similar metabolic benefit to a 300-pound person losing 30 pounds (10%). Absolute pounds don't capture this equivalence.

Can I compare my weight loss percentage to someone else's? Only loosely. Percentage is better than absolute pounds for comparison, but individual factors (starting BMI, body composition, medication dose, loss velocity) affect outcomes. Compare your percentage to clinical thresholds (5%, 10%, 15%), not to other individuals.

What is the average weight loss percentage on semaglutide? In the STEP 1 trial, average weight loss at 68 weeks was 14.9% on semaglutide 2.4 mg vs 2.4% on placebo. Real-world outcomes are typically 10% to 15% sustained loss, with about 30% of patients achieving 15%+ and 15% achieving 20%+.

What is the average weight loss percentage on tirzepatide? In the SURMOUNT-1 trial, average weight loss at 72 weeks was 15.7% on tirzepatide 15 mg, 13.4% on 10 mg, and 10.3% on 5 mg, vs 3.1% on placebo. Tirzepatide consistently produces 2 to 3 percentage points more loss than semaglutide at comparable timepoints.

Sources

1. Lean MEJ et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. The Lancet. 2018.
2. Wing RR et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. Diabetes Care. 2011.
3. Vilar-Gomez E et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015.
4. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
5. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
7. Cava E et al. Preserving healthy muscle during weight loss. Journal of Obesity. 2017.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021.
11. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021.
12. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
13. Astrup A et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet. 2009.
14. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.